CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 255 enrolled
Drug / intervention
Iodixanol +1 moredrug
Likely dose
Iodixanol 320 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01475097
NCT01475097Phase 4Completed
CompareCT.gov

A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography

GE Healthcare·interventional·Posted Nov 21, 2011·Updated Jun 11, 2014

In Brief

A Phase 4 clinical trial evaluating Iodixanol and Iopamidol for Drug Safety. Completed, enrolled 255 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral arteries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Safety
CountriesUnited States
Collaboratorsi3 Statprobe

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 21, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.6 years ago

Interventions

Iodixanoldrug

Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.

Iopamidoldrug

Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.